Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Uterine Fibroid Drug Esmya Investigated Due to Severe Liver Injuries

February 22, 2018 By Law Offices of Thomas J. Lamb, P.A.

About Esmya Esmya (ulipristal acetate) is indicated for the treatment of severe symptoms caused by uterine fibroids -- or noncancerous growths in the uterus -- in women of reproductive age. While Esmya is currently available in Europe, it is still pending FDA approval in the U.S. The active ingredient, ulipristal acetate is the same as that … [Read more...]

Filed Under: Unsafe Drugs Tagged With: EMA, esmya, esmya side effects, European Medicines Agency, hepatic failure, liver failure, liver injury, liver transplants, Pharmacovigilance Risk Assessment Committee, PRAC, ulipristal acetate, uterine fibroids treatments

Safety of Uptravi Drug Investigated After Five Patient Deaths Occur

February 15, 2017 By Law Offices of Thomas J. Lamb, P.A.

Yesterday, February 14, 2017, Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) issued a statement that it would be reviewing the safety of Uptravi after the deaths of five patients in France who were taking the drug. Uptravi (selexipag) is used as a long-term treatment for pulmonary arterial hypertension, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood pressure drugs, drug injury lawsuit, drug safety review, drug side effect, EMA, European Medicines Agency, Pharmacovigilance Risk Assessment Committee, PRAC, pulmonary arterial hypertension, selexipag, uptravi

EMA Warns that Some Diabetes Drugs Cause Increased Risk of Amputation

February 10, 2017 By Law Offices of Thomas J. Lamb, P.A.

Earlier today, February 10, 2017, the European Medicines Agency (EMA) released the findings of their Pharmacovigilance Risk Assessment Committee (PRAC) concerning the link between particular diabetes drugs and an increased risk of toe amputation. These diabetes drugs are part of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, drug injury lawsuits, drug side effects, EMA, Farxiga, forxiga, Glyxambi, Invokamet, Invokana, Jardiance, leg amputations, PRAC, toe amputations, type 2 diabetes drugs, xigduo xr

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.